{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T21:06:33Z","timestamp":1794863193294,"version":"4.9.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Conducting clinical trials in rare diseases is challenging. In trials that aim to use natural history control cohorts for evaluation of efficacy, lack of data on natural history of disease prolongs development of future therapies significantly. Therefore, collection of valid natural history data in clinical settings is needed to advance drug development. These data need to fulfill requirements on type of collection, quantifiable measures on the course of disease, verification and monitoring as well as compliance to strict data protection and sharing policies. Disease registries can be a source for patient data. Late-infantile CLN2 disease is characterized by rapid psychomotor decline and epilepsy. Natural-history data of 140 genotype-confirmed CLN2 patients from two independent, international cohorts were analyzed in a natural history study. Both datasets included quantitative ratings with disease-specific clinical scores. Among 41 patients for whom longitudinal assessments spanning an extended disease course were available within the DEM-CHILD DB (an international NCL disease patient database, NCT04613089), a rapid loss of motor and language abilities was documented in quantitative detail. Data showed that the course of disease in late-infantile CLN2 disease is highly predictable with regard to the loss of language and motor function and that the results were homogeneous across multiple and international sites. These data were accepted by EMA and FDA as valid natural-history controls for the evaluation of efficacy in experimental therapies for CLN2 disease and led to an expedited approval of intracerebroventricular enzyme replacement therapy with cerliponase alpha in May 2017.<\/jats:p>","DOI":"10.3389\/fneur.2022.785841","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T05:39:41Z","timestamp":1644298781000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials"],"prefix":"10.3389","volume":"13","author":[{"given":"Miriam","family":"Nickel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Schulz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,8]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/978-1-4612-2608-6_4","article-title":"Dementia in childhood: issues in neuropsychological assessment with application to the natural history and treatment of degenerative storage diseases","volume-title":"Advances in Child Neuropsychology","author":"Shapiro","year":"1994"},{"key":"B2","first-page":"561","article-title":"Demenzerkrankungen bei Kindern und Jugendlichen","volume":"83","author":"Kohlsch\u00fctter","year":"2015","journal-title":"P\u00e4d Praxis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1016\/j.bbadis.2015.05.007","article-title":"Human NCL neuropathology","volume":"1852","author":"Radke","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.bbadis.2013.04.008","article-title":"NCL diseases-clinical perspectives","volume":"1832","author":"Schulz","year":"2013","journal-title":"Biochim Biophys Acta."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","article-title":"Genetics of the neuronal ceroid lipofuscinoses (Batten disease)","volume":"1852","author":"Mole","year":"2015","journal-title":"Biochim Biophys Acta"},{"key":"B6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","article-title":"New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses","volume":"79","author":"Williams","year":"2012","journal-title":"Neurology."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1474-4422(18)30368-5","article-title":"Clinical challenges and future therapeutic approaches for neuronal ceroid lipofuscinosis","volume":"18","author":"Mole","year":"2019","journal-title":"Lancet Neurol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.gene.2012.12.058","article-title":"Neuronal ceroid lipofuscinosis type CLN2: a new rationale for the construction of phenotypic subgroups based on a survey of 25 cases in South America","volume":"516","author":"Kohan","year":"2013","journal-title":"Gene."},{"key":"B9","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1111\/jpc.15250","article-title":"Revealing the clinical phenotype of atypical neuronal ceroid lipofuscinosis type 2 disease: Insights from the largest cohort in the world","volume":"57","author":"Louren\u00e7o","year":"2021","journal-title":"J Paediatr Child Health."},{"key":"B10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00401-008-0349-3","article-title":"Atypical CLN2 with later onset and prolonged course: a neuropathologic study showing different sensitivity of neuronal subpopulations to TPP1 deficiency","volume":"116","author":"Elleder","year":"2008","journal-title":"Acta Neuropathol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cca.2019.02.010","article-title":"Validity of a rapid and simple fluorometric tripeptidyl peptidase 1 (TPP1) assay using dried blood specimens to diagnose CLN2 disease","volume":"492","author":"Lukacs","year":"2019","journal-title":"Clin Chim Acta"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1126\/science.277.5333.1802","article-title":"Association of mutations in a lysosomal protein with classical late-infantile neuronal ceroid lipofuscinosis","volume":"277","author":"Sleat","year":"1997","journal-title":"Science."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jnen\/62.1.1","article-title":"The neuronal ceroid-lipofuscinoses","volume":"62","author":"Haltia","year":"2003","journal-title":"J Neuropathol Exp Neurol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s10048-005-0218-3","article-title":"Correlations between genotype, ultrastructural morphology and clinical phenotype in the neuronal ceroid lipofuscinoses","volume":"6","author":"Mole","year":"2005","journal-title":"Neurogenetics."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1002\/humu.23860","article-title":"Mutation update: Review of TPP1 gene variants associated with neuronal ceroid lipofuscinosis CLN2 disease","volume":"40","author":"Gardner","year":"2019","journal-title":"Hum Mutat."},{"key":"B16","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ymgme.2007.08.124","article-title":"CLN2\/TPP1 deficiency: the novel mutation IVS7-10A>G causes intron retention and is associated with a mild disease phenotype","volume":"93","author":"Bessa","year":"2008","journal-title":"Mol Genet Metab"},{"key":"B17","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1002\/humu.21624","article-title":"Update of the mutation spectrum and clinical correlations of over 360 mutations in eight genes that underlie the neuronal ceroid lipofuscinoses","volume":"33","author":"Kousi","year":"2012","journal-title":"Hum Mutat"},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jns.2015.05.021","article-title":"Protracted late infantile ceroid lipofuscinosis due to TPP1 mutations: Clinical, molecular and biochemical characterization in three sibs","volume":"356","author":"Di Giacopo","year":"2015","journal-title":"J Neurol Sci"},{"key":"B19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.pediatrneurol.2016.02.015","article-title":"Chorea in late-infantile neuronal ceroid lipofuscinosis: an atypical presentation","volume":"60","author":"Saini","year":"2016","journal-title":"Pediatr Neurol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.seizure.2018.08.027","article-title":"Homozygous missense TPP1 mutation associated with mild late infantile neuronal ceroid lipofuscinosis and the genotype-phenotype correlation","volume":"69","author":"Chen","year":"2019","journal-title":"Seizure"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1111\/jpc.14890","article-title":"Neuronal ceroid lipofuscinosis type 2: an Australian case series","volume":"56","author":"Johnson","year":"2020","journal-title":"J Paediatr Child Health."},{"key":"B22","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1177\/0883073820977997","article-title":"Cerliponase alfa for the treatment of atypical phenotypes of CLN2 disease: a retrospective case series","volume":"36","author":"Wibbeler","year":"2021","journal-title":"J Child Neurol."},{"key":"B23","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/med\/9780199590018.003.0007","article-title":"CLN2","volume-title":"The Neuronal Ceroid Lipofuscinoses (Batten Disease)","author":"Chang","year":"2011"},{"key":"B24","first-page":"682","article-title":"CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis)","volume":"13","author":"Kohlsch\u00fctter","year":"2016","journal-title":"Pediatr Endocrinol Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/epi.13820","article-title":"Photosensitivity is an early marker of neuronal ceroid lipofuscinosis type 2 disease","volume":"58","author":"Specchio","year":"2020","journal-title":"Epilepsia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/ajmg.1320420422","article-title":"Incidence of neuronal ceroid-lipofuscinoses in West Germany: variation of a method for studying autosomal recessive disorders","volume":"42","author":"Claussen","year":"1992","journal-title":"Am J Med Genet"},{"key":"B27","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1055\/s-2007-973654","article-title":"Neuronal ceroid lipofuscinoses in Scandinavia. Epidemiology and clinical pictures","volume":"28","author":"Uvebrant","year":"1997","journal-title":"Neuropediatrics."},{"key":"B28","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1111\/j.1399-0004.2008.01054.x","article-title":"The clinical and genetic epidemiology of neuronal ceroid lipofuscinosis in Newfoundland","volume":"74","author":"Moore","year":"2008","journal-title":"Clin Genet."},{"key":"B29","unstructured":""},{"key":"B30","unstructured":""},{"key":"B31","doi-asserted-by":"crossref","DOI":"10.1055\/s-0041-1739638","article-title":"Hamburg iNCL scale: A new tool for the quantitative description of disease progression in infantile CLN1 patients","volume-title":"Presented at 17th international Congress on Neuronal Ceroid Lipofuscinosis","author":"Nickel","year":"2021"},{"key":"B32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","article-title":"Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations","volume":"112","author":"Steinfeld","year":"2002","journal-title":"Am J Med Genet."},{"key":"B33","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1111\/j.1651-2227.1988.tb10770.x","article-title":"Juvenile neuronal ceroid lipofuscinosis (JNCL): quantitative description of its clinical variability","volume":"77","author":"Kohlsch\u00fctter","year":"1988","journal-title":"Acta Paediatr Scand"},{"key":"B34","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1212\/01.wnl.0000267885.47092.40","article-title":"Neurological deterioration in late infantile neuronal ceroid lipofuscinosis","volume":"69","author":"Worgall","year":"2007","journal-title":"Neurology."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/2326409818788382","article-title":"An Adapted Clinical Measurement Tool for the Key Symptoms of CLN2 Disease","volume":"6","author":"Wyrwich","year":"2018","journal-title":"J Inborn Errors Metab Screen."},{"key":"B36","article-title":"The expanded neuronal ceroid lipofuscinosis 2 (CLN2) clinical rating scale for motor and language function: development and inter-rater reliability","volume-title":"Accepted for Posterpresentation at 17th international Congress on Neuronal Ceroid Lipofuscinosis","author":"Phillips","year":"2021"},{"key":"B37","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1212\/01.wnl.0000169019.41332.8a","article-title":"A clinical rating scale for Batten disease: reliable and relevant for clinical trials","volume":"65","author":"Marshall","year":"2005","journal-title":"Neurology"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1212\/WNL.0b013e318237f649","article-title":"Quantifying physical decline in juvenile neuronal ceroid lipofuscinosis (Batten disease)","volume":"77","author":"Kwon","year":"2011","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"e73128","DOI":"10.1371\/journal.pone.0073128","article-title":"Spectrum of ocular manifestations in CLN2-associated batten (Jansky-Bielschowsky) disease correlate with advancing age and deteriorating neurological function","volume":"8","author":"Orlin","year":"2013","journal-title":"PLoS ONE"},{"key":"B40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ajo.2020.07.015","article-title":"An ophthalmic rating scale to assess ocular involvement in juvenile CLN3 disease","volume":"220","author":"Dulz","year":"2020","journal-title":"Am J Ophthalmol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1037\/t68970-000","article-title":"Development and initial validation of the Batten's Observational Pain Scale: a preliminary study","volume":"3","author":"Breau","year":"2010","journal-title":"J Pain Manag"},{"key":"B42","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","article-title":"Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study","volume":"2","author":"Nickel","year":"2018","journal-title":"Lancet Child Adolesc Health."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1056\/NEJMoa1712649","article-title":"Study of intraventricular cerliponase alfa for CLN2 disease","volume":"378","author":"Schulz","year":"2018","journal-title":"N Engl J Med"},{"key":"B44","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/S2352-4642(18)30210-4","article-title":"Natural history data for childhood neurodegenerative disease","volume":"2","author":"Mink","year":"2018","journal-title":"Lancet Child Adolesc Health."},{"key":"B45","doi-asserted-by":"publisher","first-page":"eabb5413","DOI":"10.1126\/scitranslmed.abb5413","article-title":"Slowing late infantile Batten disease by direct brain parenchymal administration of a rh10 adeno-associated virus expressing CLN2","volume":"12","author":"Sondhi","year":"2020","journal-title":"Sci Transl Med."},{"key":"B46","unstructured":""},{"key":"B47","unstructured":""},{"key":"B48","unstructured":""}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.785841\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T05:39:45Z","timestamp":1644298785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2022.785841\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,8]]},"references-count":48,"alternative-id":["10.3389\/fneur.2022.785841"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2022.785841","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,8]]},"article-number":"785841"}}